Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case-control studies, Spain, season 2009-2010
Camelia Savulescu(Instituto de Salud Carlos III), Amparo Larrauri(Instituto de Salud Carlos III), Inmaculada Casas(Instituto de Salud Carlos III), Núria Torner(Centro de Investigación Biomédica en Red), Manuel Garcìa Cenoz(Instituto de Salud Pública de Navarra), Silvia Jiménez‐Jorge(Hospital Universitario Virgen del Rocío), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Jone M. Altzibar(Osakidetza), Antònia Pascual Galmés, Pilar Pérez Breña(Instituto de Salud Carlos III), Francisco Pozo(Instituto de Salud Carlos III), Milagros Perucha(Gobierno de La Rioja), J M Vanrell(Departament de Salut), Carolina Rodriguez(Junta de Castilla y León), Julián Mauro Ramos(Government of Extremadura), Salvador de Mateo(Instituto de Salud Carlos III), Tomás Vega, José M. Arteagoitia(Basque Government), Jesús Castilla(Instituto de Salud Pública de Navarra), Carmen Quiñones(Gobierno de La Rioja), María Concepción Serrano(Instituto de Ciencia de Materiales de Madrid)
Cited by 26
Related Papers
First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020
|Eurosurveillance|2020|715
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza
|Critical Care|2009|382
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348